Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Advisory Committee Topics Will Narrow In Response To HRG Suit - FDA

This article was originally published in The Tan Sheet

Executive Summary

FDA will ask more directed questions of its advisory committees as a way to narrow the amount of information from NDAs provided to the committees, FDA's Office of Training and Communications Director Nancy Smith, PhD, told the recent Regulatory Affairs Professionals Society annual meeting in Washington, D.C.
Advertisement

Related Content

FDA Aims To Boost Transparency Through Earlier Release Of Panel Materials
FDA Aims To Boost Transparency Through Earlier Release Of Panel Materials
FDA Aims To Boost Transparency Through Earlier Release Of Panel Materials
Postmarketing Study Status Reports Need Sponsor Pre-Clearance - PhRMA
Postmarketing Study Status Reports Need Sponsor Pre-Clearance - PhRMA
Postmarketing Study Status Reports Need Sponsor Pre-Clearance - PhRMA

Topics

Advertisement
UsernamePublicRestriction

Register

PS090456

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel